GUTS
Fractyl Health Inc.

1,203
Mkt Cap
$182.27M
Volume
635,856.00
52W High
$3.03
52W Low
$0.825
PE Ratio
-0.59
GUTS Fundamentals
Price
$1.29
Prev Close
$1.33
Open
$1.38
50D MA
$1.24
Beta
1.11
Avg. Volume
2.5M
EPS (Annual)
-$1.44
P/B
-55.32
Rev/Employee
$869.16
Loading...
Loading...
News
all
press releases
Brokers Set Expectations for Fractyl Health FY2025 Earnings
Fractyl Health, Inc. (NASDAQ:GUTS - Free Report) - Analysts at HC Wainwright lifted their FY2025 earnings per share estimates for Fractyl Health in a report issued on Thursday, November 13th. HC...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
Fractyl Health (NASDAQ:GUTS) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS
Fractyl Health (NASDAQ:GUTS - Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($0.71) earnings per share for the quarter, missing analysts' consensus...
MarketBeat·7d ago
News Placeholder
Preview: Fractyl Health's Earnings
read more...
Benzinga·9d ago
News Placeholder
Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions PR Newswire VANCOUVER, Oct. 21, 2025 Equity...
PR Newswire·1mo ago
News Placeholder
GUTS Stock Rallied About 28% Today – Here’s Why
Fractyl Health expects to file with the U.S. Food and Drug Administration for the approval of Revita in the second half of 2026.
Stocktwits·2mo ago
News Placeholder
Fractyl Health Sinks After-Hours On Stock Offering, But Investors Cheer Durable Weight Loss Data
Retail optimism surged following new real-world data showing that patients with advanced type 2 diabetes sustained weight loss and glycemic improvements two years after a single Revita procedure.
Stocktwits·4mo ago
News Placeholder
Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes
BURLINGTON, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company ), a metabolic therapeutics company focused on pioneering new approaches for the treatment of...
Globe Newswire·2y ago
News Placeholder
Fractyl Health reports Q4 EPS ($11.18) vs ($7.39) last year
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·2y ago
News Placeholder
Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Received IDE approval for the Revita Remain-1 pivotal study for weight maintenance in patients with obesity after discontinuation of GLP-1 Based Drugs Completion of enrollment in pivotal...
Globe Newswire·2y ago
News Placeholder
Fractyl Health Gains FDA Nod to Investigate Revita Device
Fractyl Health, Inc. (GUTS) just unveiled an update. Fractyl Health, Inc. has announced a significant milestone with the FDA granting it Investigational Device Exemption to explore the effectiveness...
TipRanks Financial Blog·2y ago

Latest GUTS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.